Clinical Publications and Presentations

Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) For Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results From The Single-Arm Phase 2 Study (SGN35-027 Part B)

Debulking Before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results From A Phase 3b Study

Detection of Cancer Signal For Over 50 AJCC Cancer Types With A Multi-Cancer Early-Detection Test

Performance of a targeted Methylation-Based Multi-Cancer Early Detection Test By Race/Ethnicity

Daratumumab (DARA) Maintenance Therapy Following DARA + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): End-of-Study Analysis of LYRA

CheckMate 8KX: Phase 1/2 Multitumor Preliminary Analyses of A Subcutaneous Formulation of Nivolumab (± rHuPH20)

Outreach: Preliminary Safety and Efficacy Results From A Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity setting

Preliminary Results of The Phase 2 Study of Zanubrutinib in Patients With Previously Treated B-cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib

Biologically Optimized Schedule of Gemcitabine and Nab-Paclitaxel Regimen in Metastatic Pancreatic Adenocarcinoma